Ex vivo generation of platelet products from human iPS cells View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-12-01

AUTHORS

Sou Nakamura, Naoshi Sugimoto, Koji Eto

ABSTRACT

Platelet products are used in treatments for thrombocytopenia caused by hematopoietic diseases, chemotherapy, massive hemorrhages, extracorporeal circulation, and others. Their manufacturing depends on volunteers who donate blood. However, it is becoming increasingly necessary to reinforce this blood donation system with other blood sources due to the increase in demand and shortage of supply accompanying aging societies. In addition, blood-borne infections and alloimmune platelet transfusion refractoriness are not completely resolved. Since human induced pluripotent stem cell (iPSC)-platelet products can be supplied independently from the donor, it is expected to complement current platelet products. One big hurdle with iPSC-based systems is the production of 10 units, which is equivalent to 200 billion platelets. To overcome this issue, we established immortalized megakaryocyte cell lines (imMKCLs) by introducing three transgenes, c-MYC, BMI1, and BCL-XL, sequentially into hematopoietic and megakaryocytic progenitor stage cells derived from iPSCs. The three transgenes are regulated in a Tet-ON manner, enabling the addition and depletion of doxycycline to expand and maturate the imMKCLs, respectively. In addition, we succeeded in discovering drug combinations that enable feeder-free culture conditions in the imMKCL cultivation. Furthermore, we discovered the importance of turbulence in thrombopoiesis through live bone marrow imaging and developed a bioreactor based on the concept of turbulent flow. Eventually, through the identification of two key fluid physic parameters, turbulent energy and shear stress, we succeeded in scaling up the bioreactor to qualitatively and quantitatively achieve clinically applicable levels. Interestingly, three soluble factors released from imMKCLs in the turbulent flow condition, macrophage migration inhibitory factor (MIF), insulin growth factor binding protein 2 (IGFBP2), and nardilysin (NRDC), enhanced platelet production. Based on these developments, we initiated the first-in-human clinical trial of iPSC-derived platelets to a patient with alloimmune platelet transfusion refractoriness (allo-PTR) using an autologous product. In this review, we detail current research in this field and our study about the ex vivo production of iPSC-derived platelets. More... »

PAGES

30

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s41232-020-00139-2

DOI

http://dx.doi.org/10.1186/s41232-020-00139-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1132950419

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33292717


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258799.8", 
          "name": [
            "Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakamura", 
        "givenName": "Sou", 
        "id": "sg:person.01301451753.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301451753.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258799.8", 
          "name": [
            "Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sugimoto", 
        "givenName": "Naoshi", 
        "id": "sg:person.0765060244.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765060244.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Regenerative Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-8677, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan", 
            "Department of Regenerative Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-8677, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eto", 
        "givenName": "Koji", 
        "id": "sg:person.01062427654.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062427654.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature12495", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003744109", 
          "https://doi.org/10.1038/nature12495"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-008-0147-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052506396", 
          "https://doi.org/10.1007/s12185-008-0147-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep21700", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046217351", 
          "https://doi.org/10.1038/srep21700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms11208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010149636", 
          "https://doi.org/10.1038/ncomms11208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature21706", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084128596", 
          "https://doi.org/10.1038/nature21706"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-12-01", 
    "datePublishedReg": "2020-12-01", 
    "description": "Platelet products are used in treatments for thrombocytopenia caused by hematopoietic diseases, chemotherapy, massive hemorrhages, extracorporeal circulation, and others. Their manufacturing depends on volunteers who donate blood. However, it is becoming increasingly necessary to reinforce this blood donation system with other blood sources due to the increase in demand and shortage of supply accompanying aging societies. In addition, blood-borne infections and alloimmune platelet transfusion refractoriness are not completely resolved. Since human induced pluripotent stem cell (iPSC)-platelet products can be supplied independently from the donor, it is expected to complement current platelet products. One big hurdle with iPSC-based systems is the production of 10\u2009units, which is equivalent to 200 billion platelets. To overcome this issue, we established immortalized megakaryocyte cell lines (imMKCLs) by introducing three transgenes, c-MYC, BMI1, and BCL-XL, sequentially into hematopoietic and megakaryocytic progenitor stage cells derived from iPSCs. The three transgenes are regulated in a Tet-ON manner, enabling the addition and depletion of doxycycline to expand and maturate the imMKCLs, respectively. In addition, we succeeded in discovering drug combinations that enable feeder-free culture conditions in the imMKCL cultivation. Furthermore, we discovered the importance of turbulence in thrombopoiesis through live bone marrow imaging and developed a bioreactor based on the concept of turbulent flow. Eventually, through the identification of two key fluid physic parameters, turbulent energy and shear stress, we succeeded in scaling up the bioreactor to qualitatively and quantitatively achieve clinically applicable levels. Interestingly, three soluble factors released from imMKCLs in the turbulent flow condition, macrophage migration inhibitory factor (MIF), insulin growth factor binding protein 2 (IGFBP2), and nardilysin (NRDC), enhanced platelet production. Based on these developments, we initiated the first-in-human clinical trial of iPSC-derived platelets to a patient with alloimmune platelet transfusion refractoriness (allo-PTR) using an autologous product. In this review, we detail current research in this field and our study about the ex vivo production of iPSC-derived platelets.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s41232-020-00139-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1040309", 
        "issn": [
          "1880-9693", 
          "1880-8190"
        ], 
        "name": "Inflammation and Regeneration", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "turbulent flow conditions", 
      "alloimmune platelet transfusion", 
      "importance of turbulence", 
      "turbulent flow", 
      "turbulent energy", 
      "flow conditions", 
      "shear stress", 
      "bioreactor", 
      "physics parameters", 
      "turbulence", 
      "manufacturing", 
      "applicable level", 
      "shortage of supply", 
      "flow", 
      "biggest hurdle", 
      "conditions", 
      "system", 
      "imMKCLs", 
      "energy", 
      "products", 
      "insulin growth factor binding protein 2", 
      "parameters", 
      "addition", 
      "stress", 
      "supply", 
      "production", 
      "current research", 
      "field", 
      "generation", 
      "demand", 
      "autologous products", 
      "source", 
      "units", 
      "combination", 
      "increase", 
      "concept", 
      "hurdles", 
      "shortage", 
      "issues", 
      "factors", 
      "development", 
      "imaging", 
      "lines", 
      "research", 
      "circulation", 
      "cells", 
      "study", 
      "platelets", 
      "manner", 
      "importance", 
      "feeder-free culture conditions", 
      "identification", 
      "depletion", 
      "megakaryocyte cell line", 
      "levels", 
      "cultivation", 
      "culture conditions", 
      "stem cells", 
      "platelet products", 
      "treatment", 
      "review", 
      "blood donation system", 
      "stage cells", 
      "extracorporeal circulation", 
      "protein 2", 
      "Tet", 
      "donors", 
      "pluripotent stem cells", 
      "ex vivo production", 
      "iPS cells", 
      "society", 
      "Aging Society", 
      "iPSCs", 
      "human iPS cells", 
      "blood source", 
      "volunteers", 
      "blood", 
      "nardilysin", 
      "trials", 
      "human clinical trials", 
      "vivo production", 
      "soluble factors", 
      "doxycycline", 
      "iPSCs", 
      "massive hemorrhage", 
      "bone marrow imaging", 
      "cell lines", 
      "drug combinations", 
      "marrow imaging", 
      "donation system", 
      "hemorrhage", 
      "inhibitory factor", 
      "clinical trials", 
      "patients", 
      "disease", 
      "blood-borne infections", 
      "infection", 
      "platelet production", 
      "transfusion", 
      "platelet transfusions", 
      "binding protein 2", 
      "Bcl-xL", 
      "thrombopoiesis", 
      "c-Myc", 
      "hematopoietic diseases", 
      "transgene", 
      "macrophage migration inhibitory factor", 
      "BMI1", 
      "chemotherapy", 
      "migration inhibitory factor", 
      "thrombocytopenia"
    ], 
    "name": "Ex vivo generation of platelet products from human iPS cells", 
    "pagination": "30", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1132950419"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s41232-020-00139-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33292717"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s41232-020-00139-2", 
      "https://app.dimensions.ai/details/publication/pub.1132950419"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_865.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s41232-020-00139-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s41232-020-00139-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s41232-020-00139-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s41232-020-00139-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s41232-020-00139-2'


 

This table displays all metadata directly associated to this object as RDF triples.

217 TRIPLES      21 PREDICATES      142 URIs      127 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s41232-020-00139-2 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 anzsrc-for:11
4 anzsrc-for:1102
5 schema:author Nd5b1f437227c4f04b2fe9cb05e99ea67
6 schema:citation sg:pub.10.1007/s12185-008-0147-7
7 sg:pub.10.1038/nature12495
8 sg:pub.10.1038/nature21706
9 sg:pub.10.1038/ncomms11208
10 sg:pub.10.1038/srep21700
11 schema:datePublished 2020-12-01
12 schema:datePublishedReg 2020-12-01
13 schema:description Platelet products are used in treatments for thrombocytopenia caused by hematopoietic diseases, chemotherapy, massive hemorrhages, extracorporeal circulation, and others. Their manufacturing depends on volunteers who donate blood. However, it is becoming increasingly necessary to reinforce this blood donation system with other blood sources due to the increase in demand and shortage of supply accompanying aging societies. In addition, blood-borne infections and alloimmune platelet transfusion refractoriness are not completely resolved. Since human induced pluripotent stem cell (iPSC)-platelet products can be supplied independently from the donor, it is expected to complement current platelet products. One big hurdle with iPSC-based systems is the production of 10 units, which is equivalent to 200 billion platelets. To overcome this issue, we established immortalized megakaryocyte cell lines (imMKCLs) by introducing three transgenes, c-MYC, BMI1, and BCL-XL, sequentially into hematopoietic and megakaryocytic progenitor stage cells derived from iPSCs. The three transgenes are regulated in a Tet-ON manner, enabling the addition and depletion of doxycycline to expand and maturate the imMKCLs, respectively. In addition, we succeeded in discovering drug combinations that enable feeder-free culture conditions in the imMKCL cultivation. Furthermore, we discovered the importance of turbulence in thrombopoiesis through live bone marrow imaging and developed a bioreactor based on the concept of turbulent flow. Eventually, through the identification of two key fluid physic parameters, turbulent energy and shear stress, we succeeded in scaling up the bioreactor to qualitatively and quantitatively achieve clinically applicable levels. Interestingly, three soluble factors released from imMKCLs in the turbulent flow condition, macrophage migration inhibitory factor (MIF), insulin growth factor binding protein 2 (IGFBP2), and nardilysin (NRDC), enhanced platelet production. Based on these developments, we initiated the first-in-human clinical trial of iPSC-derived platelets to a patient with alloimmune platelet transfusion refractoriness (allo-PTR) using an autologous product. In this review, we detail current research in this field and our study about the ex vivo production of iPSC-derived platelets.
14 schema:genre article
15 schema:isAccessibleForFree true
16 schema:isPartOf N3337062b4fd1404f8b67ab7cea61cdc6
17 N9ed3307c7a3c4d11accd5cf6a6ea47b0
18 sg:journal.1040309
19 schema:keywords Aging Society
20 BMI1
21 Bcl-xL
22 Tet
23 addition
24 alloimmune platelet transfusion
25 applicable level
26 autologous products
27 biggest hurdle
28 binding protein 2
29 bioreactor
30 blood
31 blood donation system
32 blood source
33 blood-borne infections
34 bone marrow imaging
35 c-Myc
36 cell lines
37 cells
38 chemotherapy
39 circulation
40 clinical trials
41 combination
42 concept
43 conditions
44 cultivation
45 culture conditions
46 current research
47 demand
48 depletion
49 development
50 disease
51 donation system
52 donors
53 doxycycline
54 drug combinations
55 energy
56 ex vivo production
57 extracorporeal circulation
58 factors
59 feeder-free culture conditions
60 field
61 flow
62 flow conditions
63 generation
64 hematopoietic diseases
65 hemorrhage
66 human clinical trials
67 human iPS cells
68 hurdles
69 iPS cells
70 iPSCs
71 identification
72 imMKCLs
73 imaging
74 importance
75 importance of turbulence
76 increase
77 infection
78 inhibitory factor
79 insulin growth factor binding protein 2
80 issues
81 levels
82 lines
83 macrophage migration inhibitory factor
84 manner
85 manufacturing
86 marrow imaging
87 massive hemorrhage
88 megakaryocyte cell line
89 migration inhibitory factor
90 nardilysin
91 parameters
92 patients
93 physics parameters
94 platelet production
95 platelet products
96 platelet transfusions
97 platelets
98 pluripotent stem cells
99 production
100 products
101 protein 2
102 research
103 review
104 shear stress
105 shortage
106 shortage of supply
107 society
108 soluble factors
109 source
110 stage cells
111 stem cells
112 stress
113 study
114 supply
115 system
116 thrombocytopenia
117 thrombopoiesis
118 transfusion
119 transgene
120 treatment
121 trials
122 turbulence
123 turbulent energy
124 turbulent flow
125 turbulent flow conditions
126 units
127 vivo production
128 volunteers
129 schema:name Ex vivo generation of platelet products from human iPS cells
130 schema:pagination 30
131 schema:productId N16286310d40f4530b06d0a75ec9f95c0
132 N96480f6b80f74e5e957205fa9e5074d7
133 Nba072c83df1c4dd3b85648713a2c6077
134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132950419
135 https://doi.org/10.1186/s41232-020-00139-2
136 schema:sdDatePublished 2022-10-01T06:48
137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
138 schema:sdPublisher N708a0eba699e4b14b12e2595502bca3f
139 schema:url https://doi.org/10.1186/s41232-020-00139-2
140 sgo:license sg:explorer/license/
141 sgo:sdDataset articles
142 rdf:type schema:ScholarlyArticle
143 N16286310d40f4530b06d0a75ec9f95c0 schema:name dimensions_id
144 schema:value pub.1132950419
145 rdf:type schema:PropertyValue
146 N3337062b4fd1404f8b67ab7cea61cdc6 schema:issueNumber 1
147 rdf:type schema:PublicationIssue
148 N3a0707504adc471a952ad7d00561b19f rdf:first sg:person.0765060244.70
149 rdf:rest N833f1aab23314b14baef33b132eb83f5
150 N708a0eba699e4b14b12e2595502bca3f schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 N833f1aab23314b14baef33b132eb83f5 rdf:first sg:person.01062427654.09
153 rdf:rest rdf:nil
154 N96480f6b80f74e5e957205fa9e5074d7 schema:name doi
155 schema:value 10.1186/s41232-020-00139-2
156 rdf:type schema:PropertyValue
157 N9ed3307c7a3c4d11accd5cf6a6ea47b0 schema:volumeNumber 40
158 rdf:type schema:PublicationVolume
159 Nba072c83df1c4dd3b85648713a2c6077 schema:name pubmed_id
160 schema:value 33292717
161 rdf:type schema:PropertyValue
162 Nd5b1f437227c4f04b2fe9cb05e99ea67 rdf:first sg:person.01301451753.77
163 rdf:rest N3a0707504adc471a952ad7d00561b19f
164 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
165 schema:name Biological Sciences
166 rdf:type schema:DefinedTerm
167 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
168 schema:name Biochemistry and Cell Biology
169 rdf:type schema:DefinedTerm
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
174 schema:name Cardiorespiratory Medicine and Haematology
175 rdf:type schema:DefinedTerm
176 sg:journal.1040309 schema:issn 1880-8190
177 1880-9693
178 schema:name Inflammation and Regeneration
179 schema:publisher Springer Nature
180 rdf:type schema:Periodical
181 sg:person.01062427654.09 schema:affiliation grid-institutes:grid.136304.3
182 schema:familyName Eto
183 schema:givenName Koji
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062427654.09
185 rdf:type schema:Person
186 sg:person.01301451753.77 schema:affiliation grid-institutes:grid.258799.8
187 schema:familyName Nakamura
188 schema:givenName Sou
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301451753.77
190 rdf:type schema:Person
191 sg:person.0765060244.70 schema:affiliation grid-institutes:grid.258799.8
192 schema:familyName Sugimoto
193 schema:givenName Naoshi
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765060244.70
195 rdf:type schema:Person
196 sg:pub.10.1007/s12185-008-0147-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052506396
197 https://doi.org/10.1007/s12185-008-0147-7
198 rdf:type schema:CreativeWork
199 sg:pub.10.1038/nature12495 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003744109
200 https://doi.org/10.1038/nature12495
201 rdf:type schema:CreativeWork
202 sg:pub.10.1038/nature21706 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084128596
203 https://doi.org/10.1038/nature21706
204 rdf:type schema:CreativeWork
205 sg:pub.10.1038/ncomms11208 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010149636
206 https://doi.org/10.1038/ncomms11208
207 rdf:type schema:CreativeWork
208 sg:pub.10.1038/srep21700 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046217351
209 https://doi.org/10.1038/srep21700
210 rdf:type schema:CreativeWork
211 grid-institutes:grid.136304.3 schema:alternateName Department of Regenerative Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-8677, Chiba, Japan
212 schema:name Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan
213 Department of Regenerative Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-8677, Chiba, Japan
214 rdf:type schema:Organization
215 grid-institutes:grid.258799.8 schema:alternateName Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan
216 schema:name Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan
217 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...